TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: major peritonitis-related morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: direct medical costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Successful structural outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bilateral favorable outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of outcomes between fellow eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: alerting scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attention control scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Implicit attitudes toward Lipitor
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skepticism toward pharmaceutical marketing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 90 days femorodistal graft patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cyclosporin AUC variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac troponin I (cTnI) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Creatinine kinase-MB (CK-MB) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average daily spontaneous bowel movements (SBM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete spontaneous bowel movements (CSBM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Abdominal discomfort or pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PQOL scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mortality at one year
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in depressive disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI for age (z score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normalized low-frequency component (LF%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Low/high-frequency component ratio (LF/HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: High-frequency component (HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participation in skin cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of endoscopical recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean errors in orientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of moderate DRPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of iatrogenic pulmonary embolism (PE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pathogen eradication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed opacification of the external iliac vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean venous density after contrast administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective rating of image quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: levels of serum E₂, LH, FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 6-month progression-free survival (6MPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Seroconversion Rate (SCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroprotection Rate (SPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Titer (SCF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean deviation degree of the SVH test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal percentages of SVH in Meniere's patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cortisol basal levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ACTH basal levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PRL basal levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: self-care self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Times to recovery of the elicited twitch response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute-complete response (CR) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of respiratory complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of proximal leg deep-vein thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of patients with pulmonary emboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Quality of Life (QOL) for the family
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ADHD Rating Scale symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in mood/anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in alcohol use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum lipoprotein profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of peritonitis episodes per patient-year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Overnight ultrafiltration volume during peritonitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma level of CGRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 24h IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to PMTCT prophylaxis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: decisional conflict score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: undetectable HCV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: mean CI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trough forced expiratory volume in one second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in IPSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Decrease in residual urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Periods of desaturation (Sa(o(2)) <95%)
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in symptoms and signs of allergic rhinitis (AR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentrations of sICAM-1 in nasal secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hearing results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month complication-free survival
Endpoint domain: Mortality/survival
Primary endpoint: device therapy survival
Endpoint domain: Mortality/survival
Primary endpoint: reduction of anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of agoraphobic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-m walking speed test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-foot up-and-go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient knowledge of risk for acute coronary syndrome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient involvement in decision making
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of admission for cardiac testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Success rate after 1 year of follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Marginal bone loss after 1 year of follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak insertion torque at surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical events (death, reinfarctions, unstable angina requiring hospitalization)
Endpoint domain: Mortality/survival
Primary endpoint: Nighttime hay fever symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Morning peak expiratory flow rates (PEFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: systolic daytime ambulatory blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to recovery from motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the curve of insulin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Amount of propofol used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary tract infection frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Gingival Thickness (GT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abdominal pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine GL-3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4(+) T-cell responses to Ag85A and Ag85B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Injection site reactions and systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Ag85A and Ag85B specific antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hamilton Depression Rating Scale (HDRS) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate (HDRS≤7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pittsburgh Sleep Quality Index (PSQI) scores
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Vitreous reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Questionnaire mean scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of LV end-diastolic volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of LV mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arm CSA increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Thigh CSA increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Squat one-repetition maximum (1 RM) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bleeding after ESD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin loss (≥2.0 g/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 6-minute walk distance (6mWD) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minnesota score reduction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Development of low back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Croup scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regimen compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative efficacy of metronidazole in suppressing bacterial vaginosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of ulcers healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance walked during 6-minute walking test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum flow rate values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGFBP‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: VO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VCO2 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VE values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pronounced cytogenetic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of those who screened as potential candidates for major depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of minor depression on the EPDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of ALS associated with plasma α‐linolenic acid (ALA)
Endpoint domain: Mortality/survival
Primary endpoint: Risk of ALS associated with plasma arachidonic acid
Endpoint domain: Mortality/survival
Primary endpoint: Risk of ALS associated with plasma docosahexaenoic acid (DHA)
Endpoint domain: Mortality/survival
Primary endpoint: Placental weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in MVC torque after NMES
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Hsup/Msup decrease after 100-Hz protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: V/Msup decrease after 60- and 100-Hz protocols
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of time spent in the near normal range of 63-140 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attachment level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody response against Bordetella pertussis antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events associated with vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: EBS clinical remission at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unprotected sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking speed at discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total dose of tramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal pain scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probing Depth (PD) reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Attachment Level (CAL) improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: supine % time pH < 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 90-day death/shock/congestive heart failure (CHF)
Endpoint domain: Mortality/survival
Primary endpoint: Microbiologic success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma nonesterified fatty acid (NEFA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improved PSE
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Major macrovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Major microvascular events
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of proved infection during hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Infection-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Clinical benefits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Index (CI) < 2.6 l/min/m(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Child-OIDP scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: prevalence of oral impacts
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Development of lipoatrophy
Endpoint domain: Adverse events/effects
Primary endpoint: opioid-positive urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surface Loss (SL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aneurysm recurrence detected by volumetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fetal growth velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: neonatal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Changes in VR-QOL
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in visual acuity (worse eye)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary pyridinium cross-links/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Deaths from cancer
Endpoint domain: Mortality/survival
Primary endpoint: American Shoulder and Elbow Surgeons score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF‐36v2 Physical Component Summary
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bodily Pain Domain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinically improved disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total WURSS‐21‐K score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified CEAP clinical score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of analgesic tablets
Endpoint domain: Adverse events/effects
Primary endpoint: Postinterventional pain
Endpoint domain: Adverse events/effects
Primary endpoint: Fasting hs-CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Flow-mediated vasodilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the triglyceride curve (TG-AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total lean body mass (LBM) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total fat mass decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Behavioral and psychological symptoms of dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Atrial Fibrillation (POAF)
Endpoint domain: Physiological/clinical
Primary endpoint: Stroke
Endpoint domain: Physiological/clinical
Primary endpoint: Length of Stay (LOS)
Endpoint domain: Resource use
Primary endpoint: Liver Function Tests (LFTs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-fatal myocardial infarction and fatal coronary heart disease
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of salivary levels of mutans streptococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of salivary levels of lactobacilli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active phase of labor duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for oxytocin augmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal heart rate decelerations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes